User login
Researchers conducting a multicenter study in Italy evaluating the stability of coadministering a combined MMR plus varicella (MMRV) vaccine with conjugated meningococcal C (MenC) vaccine found MMRV and MenC immunogenic and well tolerated in children aged 13-15 months.
A total of 716 children aged 13-15 months were randomized (2:1:1) and received a single dose of each vaccine, which included coadministered MMRV plus MenC at the same visit (MMRV + MenC group), or MMRV followed 42 days later by MenC (MMRV group), or MenC followed 42 days later by MMRV (MenC group).
The MMRV seroconversion rates 42 days post vaccination were 99.3% (measles), 94.5% (mumps), 100% (rubella), and 99.7% (varicella) in the MMRV plus MenC group, and 99.4%, 93.2%, 100%, and 100%, respectively, in the MMRV group. Noninferiority was demonstrated.
The seroprotection rate for rSBAMenC in the MMRV + MenC group was 98.3%, compared with 99.3% in children who received just MenC, at 42 days post vaccination. Noninferiority was demonstrated.
“The study vaccines were generally well tolerated, and clinically acceptable safety profiles were observed,” Paolo Durando of the University of Genoa (Italy) and his associates reported.
Read more of the article in Vaccine here (2016.doi:10.1016/j.vaccine.2016.07.009).
Researchers conducting a multicenter study in Italy evaluating the stability of coadministering a combined MMR plus varicella (MMRV) vaccine with conjugated meningococcal C (MenC) vaccine found MMRV and MenC immunogenic and well tolerated in children aged 13-15 months.
A total of 716 children aged 13-15 months were randomized (2:1:1) and received a single dose of each vaccine, which included coadministered MMRV plus MenC at the same visit (MMRV + MenC group), or MMRV followed 42 days later by MenC (MMRV group), or MenC followed 42 days later by MMRV (MenC group).
The MMRV seroconversion rates 42 days post vaccination were 99.3% (measles), 94.5% (mumps), 100% (rubella), and 99.7% (varicella) in the MMRV plus MenC group, and 99.4%, 93.2%, 100%, and 100%, respectively, in the MMRV group. Noninferiority was demonstrated.
The seroprotection rate for rSBAMenC in the MMRV + MenC group was 98.3%, compared with 99.3% in children who received just MenC, at 42 days post vaccination. Noninferiority was demonstrated.
“The study vaccines were generally well tolerated, and clinically acceptable safety profiles were observed,” Paolo Durando of the University of Genoa (Italy) and his associates reported.
Read more of the article in Vaccine here (2016.doi:10.1016/j.vaccine.2016.07.009).
Researchers conducting a multicenter study in Italy evaluating the stability of coadministering a combined MMR plus varicella (MMRV) vaccine with conjugated meningococcal C (MenC) vaccine found MMRV and MenC immunogenic and well tolerated in children aged 13-15 months.
A total of 716 children aged 13-15 months were randomized (2:1:1) and received a single dose of each vaccine, which included coadministered MMRV plus MenC at the same visit (MMRV + MenC group), or MMRV followed 42 days later by MenC (MMRV group), or MenC followed 42 days later by MMRV (MenC group).
The MMRV seroconversion rates 42 days post vaccination were 99.3% (measles), 94.5% (mumps), 100% (rubella), and 99.7% (varicella) in the MMRV plus MenC group, and 99.4%, 93.2%, 100%, and 100%, respectively, in the MMRV group. Noninferiority was demonstrated.
The seroprotection rate for rSBAMenC in the MMRV + MenC group was 98.3%, compared with 99.3% in children who received just MenC, at 42 days post vaccination. Noninferiority was demonstrated.
“The study vaccines were generally well tolerated, and clinically acceptable safety profiles were observed,” Paolo Durando of the University of Genoa (Italy) and his associates reported.
Read more of the article in Vaccine here (2016.doi:10.1016/j.vaccine.2016.07.009).
FROM VACCINE
